When blood
formation
changes.
Hematologic diseases include non-malignant and malignant disorders affecting blood cells, bone marrow, and hematopoietic or lymphoid tissues.
Explore how abnormalities in cellular production, differentiation, survival, and clonal regulation contribute to different disease processes.
Explore the disease atlas ↓Reduced production
Some disorders reduce the production of one or more blood cell populations.
Altered differentiation
Abnormal development may affect cellular maturation and blood counts.
Clonal expansion
Certain acquired mutations can support expansion of particular clones.
Hematologic disorders may arise from problems in blood cell production, cell destruction, immune regulation, or abnormal cellular proliferation. Not all hematologic disorders are cancers.
A spectrum of
blood disorders.
Hematologic diseases include a wide range of conditions with different biological mechanisms. Some involve decreased blood cell production, increased peripheral destruction, defective hemoglobin, or abnormalities in coagulation.
Other diseases involve acquired genetic changes that alter hematopoietic cell growth, differentiation, or survival. These may give rise to clonal hematologic neoplasms.
Red Cell Disorders
Include nutritional anemia, hemolytic anemia, inherited hemoglobin disorders, and other causes of altered red cell mass or function.
Bone Marrow Failure
Involves insufficient production of blood cells, as seen in disorders including acquired aplastic anemia.
Myeloid Neoplasms
Include acute myeloid leukemia, myelodysplastic neoplasms, myeloproliferative neoplasms, and overlap disorders.
Lymphoid Neoplasms
Include many lymphomas, lymphoid leukemias, and plasma cell neoplasms.
These broad educational categories are not a complete clinical taxonomy. Specific diagnoses use established disease classifications integrating morphology, immunophenotype, genetic findings, and clinical context.
When the system
produces too little.
Anemia is a condition characterized by reduced hemoglobin concentration, often accompanied by changes in red blood cell number or mass. It can result from insufficient production, blood loss, or increased destruction of erythrocytes.
Iron deficiency, vitamin deficiencies, inflammation, kidney disease, hemoglobin disorders, and bone marrow abnormalities are among the many potential causes of anemia. The biological mechanism matters because anemia is a finding, not a single disease entity.
Aplastic anemia is a bone marrow failure syndrome involving markedly reduced hematopoietic cell production. Acquired cases often involve immune-mediated injury to hematopoietic stem and progenitor populations.
Bone marrow failure can also be inherited or associated with other acquired disorders. Distinguishing the underlying cause requires clinical evaluation and appropriate laboratory studies.
Anemia, neutropenia and thrombocytopenia describe different abnormalities in blood counts. They may occur independently or together and do not by themselves identify a specific underlying diagnosis.
When myeloid cells
become abnormal.
Myeloid neoplasms involve clonal disorders of hematopoietic cells with myeloid developmental potential. Their classification considers disease morphology, differentiation, molecular alterations, and clinical findings.
Acute myeloid leukemia (AML) is a genetically and biologically heterogeneous malignancy characterized by abnormal myeloid precursor expansion and impaired normal hematopoiesis.
Myelodysplastic neoplasms (MDS), historically called myelodysplastic syndromes, are clonal marrow disorders typically associated with cytopenias and ineffective or dysplastic blood cell development.
Myeloproliferative neoplasms (MPNs) are clonal disorders characterized by abnormal proliferation of one or more myeloid lineages. Examples include polycythemia vera, essential thrombocythemia, and primary myelofibrosis.
Some neoplasms have overlapping myelodysplastic and myeloproliferative features. Chronic myelomonocytic leukemia is one example in this overlap category.
Genetic findings can help define certain disease entities. For example, BCR::ABL1 is central to chronic myeloid leukemia, while alterations involving JAK2, CALR and MPL are relevant in selected MPNs. None of these tests should be interpreted in isolation from clinical findings.
Disorders of the
immune lineages.
Lymphoid neoplasms arise from different stages of B-cell, T-cell, or NK-cell development. The category includes diverse forms of lymphoma and lymphoid leukemia.
Lymphomas commonly involve lymph nodes or other tissues, although blood and bone marrow involvement can occur. Leukemic presentations often involve substantial peripheral blood or bone marrow disease.
These distinctions are not absolute: certain lymphoid neoplasms can present in leukemic or tissue-based forms. Classification depends on cell identity and disease biology rather than anatomical location alone.
Plasma cell neoplasms, including multiple myeloma, arise from antibody-producing cells of B-cell lineage. Their biology and clinical presentation differ from many other lymphoid malignancies.
Flow cytometry, immunohistochemistry, cytogenetics and molecular studies can help establish lymphoid lineage identity and distinguish disease entities.
Clonal expansion
is not always cancer.
During life, hematopoietic stem and progenitor cells can acquire somatic genetic variants. Some variants confer a selective advantage, allowing particular clones to increase their contribution to circulating blood cells.
This biological process can give rise to clonal hematopoiesis. It becomes increasingly common with age and is associated with several important research questions about inflammation, aging, and disease susceptibility.
Clonal hematopoiesis of indeterminate potential, commonly called CHIP, is a defined category involving particular somatic mutations in individuals without an established hematologic malignancy or otherwise explanatory blood count abnormalities.
Clonal cytopenia of undetermined significance, or CCUS, is a separate category involving persistent otherwise unexplained cytopenia with evidence of relevant clonality, without meeting criteria for a defined myeloid neoplasm.
Clonal hematopoiesis is not equivalent to leukemia. Risk varies with the affected genes, clone size, coexisting mutations and clinical circumstances. Many individuals with clonal hematopoiesis do not develop blood cancer.
From blood counts
to molecular evidence.
Hematologic investigation begins with the clinical context, including symptoms, medical history, examination, and patterns in laboratory measurements.
The complete blood count provides information about hemoglobin, leukocyte populations and platelets. Peripheral blood examination may reveal morphological abnormalities that help guide further investigation.
Some clinical questions require bone marrow examination, immunophenotyping, cytogenetic analysis, or targeted molecular testing. The selection and interpretation of these investigations depend on the suspected disorder.
Cellular Analysis
Blood counts, blood film morphology and marrow examination can assess production and maturation.
Immunophenotyping
Flow cytometry helps characterize cell populations and abnormal phenotypes.
Genomic Analysis
Cytogenetic and molecular methods can identify alterations relevant to disease classification.
Comparative disease reference
| Disease group | Biological feature | Research focus |
|---|---|---|
| Anemia | Reduced hemoglobin due to multiple possible mechanisms | Erythropoiesis, iron metabolism and red cell survival |
| Aplastic anemia | Insufficient marrow blood cell production | Stem cell depletion and immune-mediated injury |
| MDS | Clonal marrow neoplasm with dysplasia and cytopenias | Ineffective hematopoiesis and molecular alterations |
| MPN | Clonal proliferation of myeloid populations | Growth signaling and disease-associated mutations |
| Acute leukemia | Abnormal precursor-cell proliferation | Differentiation arrest and genetic classification |
| Lymphoid neoplasms | Clonal lymphoid or plasma cell proliferation | Lineage identity and molecular pathogenesis |
These descriptions are educational. No isolated laboratory result, mutation, symptom or visual illustration on this page establishes a diagnosis. Medical assessment requires appropriately qualified healthcare professionals.
Understanding disease
through cellular biology.
Research into hematologic diseases has contributed to major advances in molecular biology, stem cell science, transplantation and cellular therapeutics.
Disease models using hematopoietic cell cultures, genetically modified cells, and patient-derived samples provide opportunities to investigate specific biological mechanisms.
Single-cell transcriptomics, molecular profiling, lineage tracing and spatial tissue analysis help researchers examine how abnormal populations arise and interact with surrounding cells.
These approaches are increasingly important for understanding tumor heterogeneity, treatment resistance and the relationship between hematopoietic cell populations and their microenvironments.
The connection between disease classification and fundamental hematopoietic biology illustrates why blood formation remains an essential area of biomedical research.
Disease reveals
the limits of
regulation.
Studying hematologic disorders helps scientists understand the molecular processes required for normal blood formation.
From stem cell failure to abnormal clonal proliferation, each disease category provides insight into cellular regulation, differentiation, genomic integrity and tissue interactions.
Explore Research Methods ↗